CHALLENGES AND OPPORTUNITIES IN VALUE ASSESSMENT OF INNOVATIVE BIOLOGIC MEDICINES

ISPOR 8TH ASIA-PACIFIC CONFERENCE
AMGEN SPONSORED SYMPOSIUM
LUNCH TIME 12:15-13:15, 11 SEPTEMBER 2018, TOKYO, JAPAN

SEPTEMBER 11, 2018

DISCLAIMER

<Off-label information>
Contents of the session may contain information that is not within the approved product labeling and has not otherwise been approved in Japan.
Please refer to the package inserts of a respective drug for its labeling.

<CASE REPORT>
Contents of the session may contain information of a drug, such as effectiveness, as a case report. The report is not meant to be used, nor should it be used, to diagnose or treat any medical condition.
Please refer to the package inserts of a respective drug for its labeling.

<Information of products not marketed by Amgen and its affiliates>
Contents of the session may contain information that is related to products not marketed by Amgen and its affiliates.
Please refer to the package inserts of a respective drug for its labeling.

Astellas Amgen BioPharma K.K.
DESCRIPTION

Background:
- The public understanding of innovative biologic medicines is low
- In a Government funding model, these new medicines are considered in relation to the value that other medicines already funded can provide
- Because the costs of innovative biologic medicines relate to the health benefit derived, as well as a range of other factors, the perceived price differential may appear high
- Potential challenges in patient access to new medicines, or reimbursement.
- In a private-pay model, individuals must consider the cost of medicines relative to their ability to pay

Symposia concept:
- Why are innovative biologic medicines needed?
- What is the unique value that innovative biologic medicines bring?
- How can the value of innovative biologic medicines be appropriately assessed and evaluated, particularly from a payers’ perspective?
- How can the value of innovative biologic medicines be best communicated?

WHILST BIOLOGICS HAVE BEEN AVAILABLE FOR SOME TIME, THEY ARE STILL NOT WELL UNDERSTOOD

- Familiarity with the term biosimilar: “Which of the following best describes how familiar you are with the term biosimilar?”
- Similar outcomes for specialists (~80% understood)
- Much lower level of understanding with consumers (~40% understood)

Source: The Australian Biologic and Biosimilar Medicines 2020 Forum 2016
AGENDA

Moderator:

Marty Jovic, Partner, Health Economics & Policy, PWC Australia

Speakers:

- Dr. Martin Zagari, Vice President and Head, Global Health Economics, Amgen Inc., USA
  • Why are Biological Medicines the Future of Medicine – a scientific/clinical rationale of the need for biologics, their unique/special values, and an overall framework for value assessment

- Prof. Junya Ako, Professor and Chairman, Department of Cardiovascular Medicine, Kitasato University, Japan
  • Clinical and economic values of innovative biologics for cardiovascular disease and what are the appropriate ways to assess their value

- Prof. Jeonghoon Ahn, Associate Professor, Ewha Womans University, South Korea
  • Clinical and economic value of innovative biologics for osteoporosis and what are the appropriate ways to assess their value

- Prof. Jinxing Ding, Professor and Vice Dean, China Pharmaceutical University, China
  • Value assessment and market access of innovative biologics in China